Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Movers shakers: Volumes of Indiabulls Ventures, Shriram Transport rose the most in last 5 days

2018-07-04 moneycontrol
The market was on an uptrend this Wednesday afternoon with the Nifty up 70 points at 10,770 and the Sensex gaining 262 points at 35,641.
GRASIM GRSJY GRAPHITE IBVENTURES 532967 SRTRANSFIN KIRIINDUS IDBLZ 511218 532960 GRSXY SRRQY 500300 509488

14
IT stocks back in favour on weak rupee, cheap valuations

2018-06-24 livemint
Mumbai: Of the 10 top-performing BSE 200 companies, five are from the information technology (IT) sector, signalling a revival in the Indian software services industry on the back of an improving US economy and a depreciating rupee, besides relatively attractive valuations.
KMBKY IBVENTURES BNPQY TCHQY BNPQF TTNQY 532755 IDBLZ TECHM 532960 BNPZY 532540 BAJFINANCE KOTAKBANK BJJQY TCS 500247 MNDQY 500034

19
Market Update: Pharma stocks extend gains with Lupin up 5%; TCS, RIL most active

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 47 points at 10,834 and the Sensex added 177 points at 35,661.
500408 500325 AUROPHARMA RELIANCE TTQQY 532714 HINDUNILVR 511389 VIDEOIND IDBLZ HCL-INSYS CADILAHC TATACHEM 532960 JUSTDIAL 532321 535648 532187 532483 RIGD 500696 500179 BJJQY KEC 500770 RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK IBVENTURES CDLYY CNRYY BAJFINANCE ARBQY TATAELXSI CANBK JSTQY

5
BSE brings 109 firms under enhanced surveillance

2018-06-04 moneycontrol
Leading stock exchange BSE today decided to bring 109 companies, including Reliance Naval and Engineering, Amtek Auto, GVK Power & Infrastructure under enhanced surveillance measures. "...100 percent margins shall be applicable with effect from June 6, 2018 on all open positions as on June 5, 2018 and new positions created from June 6, 2018 onwards," the exchange said in a circular.
532960 AMKD RAIN 533207 JPINFRATEC IBVENTURES 500339 AMTEKAUTO 520077 IDBLZ 532775 GTLINFRA

3
PM Modi#39;s 4 years in office: A few hits and misses D-Street is talking about

2018-05-27 moneycontrol
Equity benchmarks in the four years of Modi government being in power had a good run. The Sensex and Nifty, between May 26, 2014 and May 25, 2018 managed to surge around 44-45 percent.
532960 511605 IBVENTURES ARIHCAPM IDBLZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...